{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:53:42Z","timestamp":1794009222181,"version":"4.8.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.biopha.2020.110708","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:43:02Z","timestamp":1599781382000},"page":"110708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":627,"special_numbering":"C","title":["Type II diabetes mellitus: a review on recent drug based therapeutics"],"prefix":"10.1016","volume":"131","author":[{"given":"Santwana","family":"Padhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-0956","authenticated-orcid":false,"given":"Anindita","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110708_bib0005","doi-asserted-by":"crossref","first-page":"172625","DOI":"10.1016\/j.ejphar.2019.172625","article-title":"Treatment strategies against diabetes: Success so far and challenges ahead","volume":"862","author":"Khursheed","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes. Care"},{"key":"10.1016\/j.biopha.2020.110708_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.09.003","article-title":"Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment","volume":"264","author":"Wong","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2020.110708_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2017.00006","article-title":"Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management","volume":"8","author":"Chaudhury","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0025","series-title":"Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes","author":"Feingold","year":"2000"},{"key":"10.1016\/j.biopha.2020.110708_bib0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.dsx.2018.10.008","article-title":"Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention","volume":"13","author":"Tan","year":"2019","journal-title":"Diabetes. Metab. Syndr."},{"key":"10.1016\/j.biopha.2020.110708_bib0035","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.3390\/molecules24234209","article-title":"Nanoparticle Delivery Systems in the Treatment of Diabetes Complications","volume":"24","author":"Souto","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2020.110708_bib0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.actbio.2018.09.049","article-title":"Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy","volume":"81","author":"Uppal","year":"2018","journal-title":"Acta. Biomater."},{"key":"10.1016\/j.biopha.2020.110708_bib0045","first-page":"177","article-title":"Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ","volume":"11","author":"Abbasi","year":"2016","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0050","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1248\/bpb.b13-00369","article-title":"Functional Alterations of Intestinal P-Glycoprotein under Diabetic Conditions","volume":"36","author":"Kobori","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2020.110708_bib0055","first-page":"61","article-title":"Diabetes Mellitus: A Review on Pathophysiology, Current Status of Oral Pathophysiology, Current Status of Oral Medications and Future Perspectives","volume":"55","author":"Okur","year":"2017","journal-title":"ACTA Pharm Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14341\/2072-0351-6248","article-title":"Insulin resistance in pathogenesis of type 2 diabetes mellitus","volume":"14","author":"Mayorov","year":"2011","journal-title":"Diabetes. Mellitus."},{"key":"10.1016\/j.biopha.2020.110708_bib0065","first-page":"57","article-title":"Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus","volume":"11","author":"Ojha","year":"2019","journal-title":"Clin Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0070","first-page":"41","article-title":"Pathophysiology of Type 2 Diabetes and Its Treatment Policy","volume":"53","author":"Kaku","year":"2010","journal-title":"JMAJ"},{"key":"10.1016\/j.biopha.2020.110708_bib0075","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and Treatment of Type 2 Diabetes: Perspectives on the Past, Present and Future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110708_bib0080","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1177\/0145721715607642","article-title":"Role of Amylin in Type 1 and Type 2 Diabetes","volume":"41","author":"Hieronymus","year":"2015","journal-title":"Diabetes. Educ."},{"key":"10.1016\/j.biopha.2020.110708_bib0085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/nutrit\/nuu012","article-title":"Glucose transporters: cellular links to hyperglycaemia in insulin resistance and diabetes","volume":"73","author":"Stringer","year":"2015","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.biopha.2020.110708_bib0090","series-title":"Pharmacology","first-page":"408","author":"Rang","year":"2003"},{"key":"10.1016\/j.biopha.2020.110708_bib0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.110708_bib0100","first-page":"26","article-title":"A review article- gestational diabetes mellitus","volume":"7","author":"Akhalya","year":"2019","journal-title":"Endocrinol. Metab. Int. J."},{"key":"10.1016\/j.biopha.2020.110708_bib0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0098-8","article-title":"Gestational diabetes mellitus","volume":"5","author":"McIntyre","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.biopha.2020.110708_bib0110","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/926713","article-title":"Genetics of Type 2 Diabetes: Insights into the Pathogenesis and Its Clinical Application","volume":"2014","author":"Sun","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.biopha.2020.110708_bib0115","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00020","article-title":"Cystic Fibrosis-Related Diabetes","volume":"9","author":"Kayani","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0120","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9826930","article-title":"Diabetes in HFE Hemochromatosis","author":"Barton","year":"2017","journal-title":"J. Diabetes. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0125","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fendo.2018.00284","article-title":"Diabetes Mellitus Secondary to Cushing\u2019s disease","volume":"9","author":"Barbot","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fendo.2018.00358","article-title":"Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment","volume":"9","author":"Ferra\u00f9","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0135","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/390534","article-title":"The Relationship between Type 2 Diabetes Mellitus and Related Thyroid Diseases","volume":"2013","author":"Wang","year":"2013","journal-title":"J. Diabetes. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0140","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.3748\/wjg.v19.i42.7276","article-title":"Diagnosis and treatment of diabetes mellitus in chronic pancreatitis","volume":"19","author":"Ewald","year":"2013","journal-title":"World. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2020.110708_bib0145","first-page":"144","article-title":"Diabetes Type 2 and Pancreatic Cancer: A History Unfolding","volume":"17","author":"De Souza","year":"2016","journal-title":"JOP"},{"key":"10.1016\/j.biopha.2020.110708_bib0150","article-title":"Corticosteroids are used to reduce harmful inflammation but can lead to diabetes - often referred to as steroid diabetes","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.110708_bib0155","doi-asserted-by":"crossref","DOI":"10.1186\/1758-5996-3-2","article-title":"Understanding diabetes in patients with HIV\/AIDS","volume":"3","author":"Kalra","year":"2011","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.biopha.2020.110708_bib0160","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.7150\/ijms.10001","article-title":"Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention","volume":"11","author":"Wu","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0165","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-014-0520-2","article-title":"Young Children with Type 1 Diabetes: Challenges, Research, and Future Directions","volume":"14","author":"Streisand","year":"2014","journal-title":"Curr. Diabetes. Rep."},{"key":"10.1016\/j.biopha.2020.110708_bib0170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 Diabetes Mellitus: A Review of Current Trends","volume":"27","author":"Olokoba","year":"2012","journal-title":"Oman Med. J."},{"key":"10.1016\/j.biopha.2020.110708_bib0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/dmrr.2515","article-title":"Effect of diet on type 2 diabetes mellitus: a review","volume":"30","author":"Khazrai","year":"2014","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.biopha.2020.110708_bib0180","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.2337\/dc11-0447","article-title":"Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?","volume":"34","author":"Eckel","year":"2011","journal-title":"Diabetes Care."},{"key":"10.1016\/j.biopha.2020.110708_bib0185","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bbadis.2017.01.016","article-title":"Dynamics of diabetes and obesity: Epidemiological perspective","volume":"1863","author":"Boles","year":"2017","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"10.1016\/j.biopha.2020.110708_bib0190","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2337\/db11-1360","article-title":"Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes: Results from a Long-Term Prospective Study","volume":"61","author":"Gambineri","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.110708_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/3086167","article-title":"Complications of Diabetes 2017","volume":"2018","author":"Papatheodorou","year":"2018","journal-title":"J. Diabetes. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4239\/wjd.v8.i12.489","article-title":"Gestational diabetes from A to Z","volume":"8","author":"Mirghani Dirar","year":"2017","journal-title":"World. J. Diabetes."},{"key":"10.1016\/j.biopha.2020.110708_bib0205","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.12995","article-title":"\u03b2-Cell signalling and insulin secretagogues: A path for improved diabetes therapy","volume":"19","author":"Seino","year":"2017","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijem.IJEM_556_17","article-title":"Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus \u2013 International Task Force","volume":"22","author":"Kalra","year":"2018","journal-title":"Indian J. Endocr. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0215","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"State of the art paper Sulfonylureas and their use in clinical practice","volume":"4","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0220","first-page":"1","article-title":"Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus","volume":"10","author":"Hemmingsen","year":"2016","journal-title":"Cochrane Database. Syst. Rev."},{"key":"10.1016\/j.biopha.2020.110708_bib0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/21548331.1999.11443925","article-title":"Improving Management of Type 2 Diabetes Mellitus: 2. Biguanides","volume":"34","author":"Quillen","year":"1999","journal-title":"Hosp. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0230","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.3390\/ijms20133316","article-title":"Phenformin as an Anticancer Agent: Challenges and Prospects","volume":"20","author":"Rubi\u00f1o","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0235","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00125-009-1639-6","article-title":"Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase","volume":"53","author":"Bourron","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2020.110708_bib0240","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: clinical use in type 2 diabetes","volume":"60","author":"Sanchez-Rangel","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2020.110708_bib0245","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0250","first-page":"1","article-title":"Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs","volume":"2017","author":"Thangavel","year":"2017","journal-title":"Int. J. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110708_bib0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18773\/austprescr.2004.059","article-title":"Experimental and clinical pharmacology: Thiazolidinediones - mechanisms of action","volume":"27","author":"Greenfield","year":"2004","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.biopha.2020.110708_bib0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the Forgotten Diabetes Medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr. Diabetes. Rep."},{"key":"10.1016\/j.biopha.2020.110708_bib0265","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874467212666190111165015","article-title":"A Contemporary Overview of PPAR\u03b1\/\u03b3 Dual Agonists for the Management of Diabetic Dyslipidemia","volume":"12","author":"Balakumar","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0270","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/978687","article-title":"Idealized PPAR\u03b3-Based Therapies: Lessons from Bench and Bedside","volume":"2012","author":"Amato","year":"2012","journal-title":"PPAR Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2277-9531.127541","article-title":"The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern","volume":"3","author":"Asif","year":"2014","journal-title":"J. Edu. Health Promot."},{"key":"10.1016\/j.biopha.2020.110708_bib0280","series-title":"Alpha-Glucosidase Inhibitors for Diabetes, Precose & Glyset for Type 2 Diabetes","year":"2019"},{"key":"10.1016\/j.biopha.2020.110708_bib0285","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00253-003-1477-2","article-title":"Biotechnology and molecular biology of the \u03b1 - glucosidase inhibitor acarbose","volume":"63","author":"Wehmeier","year":"2004","journal-title":"Appl. Microbiol. Biot."},{"key":"10.1016\/j.biopha.2020.110708_bib0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1463-1326.2011.01526.x","article-title":"Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients","volume":"14","author":"Narita","year":"2011","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0295","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2710.2009.01132.x","article-title":"Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin","volume":"35","author":"Derosa","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0300","article-title":"Alpha-glucosidase inhibitors","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.110708_bib0305","doi-asserted-by":"crossref","first-page":"899","DOI":"10.5114\/aoms.2012.31621","article-title":"Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents \u03b1-Glucosidase inhibitors and their use in clinical practice","volume":"5","author":"Derosa","year":"2012","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0310","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/dme.12376","article-title":"The use of oral hypoglycaemic agents in pregnancy","volume":"31","author":"Holt","year":"2014","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2020.110708_bib0315","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1874104501105010078","article-title":"Amylin Analogues in the Treatment of Diabetes Mellitus: Medicinal Chemistry and Structural Basis of its Function","volume":"5","author":"Adeghate","year":"2011","journal-title":"Open. J. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110708_bib0320","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin Agonists: A Novel Approach in the Treatment of Diabetes","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.110708_bib0325","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/VHRM.S1978","article-title":"Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk","volume":"4","author":"Hoogwerf","year":"2008","journal-title":"Vasc. Health. Risk. Manag."},{"key":"10.1016\/j.biopha.2020.110708_bib0330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DMSO.S7004","article-title":"Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes; a review","volume":"3","author":"Hansen","year":"2010","journal-title":"Diabetes. Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2020.110708_bib0335","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.2337\/db17-0058","article-title":"Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine","volume":"66","author":"Sun","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.110708_bib0340","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.110708_bib0345","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.biopha.2020.110708_bib0350","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(19)31350-9","article-title":"Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?","volume":"394","author":"Holst","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110708_bib0355","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2012.0022","article-title":"Non-Insulin Injectable Treatments (Glucagon-Like Peptide-1 and Its Analogs) and Cardiovascular Disease","volume":"14","author":"Lebovitz","year":"2012","journal-title":"Diabetes. Technol. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0360","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.metabol.2019.06.012","article-title":"Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin","volume":"98","author":"Alexopoulos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2020.110708_bib0365","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/2230-8210.111625","article-title":"Glucagon-like peptide-1 analogues: An overview","volume":"17","author":"Gupta","year":"2013","journal-title":"Indian J. Endocr. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0370","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/jm500810s","article-title":"Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications","volume":"58","author":"Manandhar","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110708_bib0375","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2020.110708_bib0380","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00260","article-title":"From the Incretin Concept and the Discovery of GLP-1 to Today\u2019s Diabetes Therapy","volume":"10","author":"Holst","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2042018814558242","article-title":"Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus","volume":"6","author":"Harris","year":"2015","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0390","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1515\/jtim-2017-0015","article-title":"The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes","volume":"5","author":"St Onge","year":"2017","journal-title":"J. Transl. Int. Med."},{"key":"10.1016\/j.biopha.2020.110708_bib0395","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13300-018-0420-6","article-title":"Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk","volume":"9","author":"Goncalves","year":"2018","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0400","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0405","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit. Rev. Cl. Lab. Sci"},{"key":"10.1016\/j.biopha.2020.110708_bib0410","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/CS20040302","article-title":"Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders","volume":"108","author":"Gorrell","year":"2005","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0415","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical Use of DPP-4 Inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes. Obes. 24"},{"key":"10.1016\/j.biopha.2020.110708_bib0425","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, Efficacy and Safety of Sodium\u2013Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2020.110708_bib0430","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"10.1016\/j.biopha.2020.110708_bib0435","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4103\/ijem.IJEM_162_17","article-title":"Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus","volume":"22","author":"Kalra","year":"2018","journal-title":"Indian J. Endocr. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0440","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4093\/dmj.2017.41.5.349","article-title":"Monotherapy in Patients with Type 2 Diabetes Mellitus","volume":"41","author":"Rhee","year":"2017","journal-title":"Diabetes. Metab. J."},{"key":"10.1016\/j.biopha.2020.110708_bib0445","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients: Variations with increasing levels of HbA1c","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes. Care."},{"key":"10.1016\/j.biopha.2020.110708_bib0450","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/dc06-1120","article-title":"Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy: A meta-regression analysis","volume":"29","author":"Bloomgarden","year":"2006","journal-title":"Diabetes. Care."},{"key":"10.1016\/j.biopha.2020.110708_bib0455","first-page":"OE08","article-title":"Implications of Postprandial Hyperglycaemia and Role of Voglibose in Type 2 Diabetes Mellitus","volume":"12","author":"Pattanaik","year":"2018","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0460","first-page":"3023","article-title":"Voglibose: An Alpha Glucosidase Inhibitor","volume":"7","author":"Dabhi","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0465","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.diabres.2008.11.009","article-title":"Comparison of pre- versus post-meal administration of voglibose in men with or without impaired glucose tolerance","volume":"83","author":"Aoki","year":"2009","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0470","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.nut.2008.11.015","article-title":"The \u03b1-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes","volume":"25","author":"Fukaya","year":"2009","journal-title":"Nutrition"},{"key":"10.1016\/j.biopha.2020.110708_bib0475","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.metabol.2004.10.004","article-title":"Effect of two \u03b1-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms","volume":"54","author":"Fujisawa","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2020.110708_bib0480","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/0063030-200822060-00004","article-title":"Pramlintide in the Treatment of Diabetes Mellitus","volume":"22","author":"Edelman","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.biopha.2020.110708_bib0485","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diaspect.23.2.124","article-title":"Pramlintide: Clinical Strategies for Success","volume":"23","author":"Alrefai","year":"2010","journal-title":"Diabetes. Spectr."},{"key":"10.1016\/j.biopha.2020.110708_bib0490","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: Current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2020.110708_bib0495","doi-asserted-by":"crossref","first-page":"115070","DOI":"10.1016\/j.bmc.2019.115070","article-title":"Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties","volume":"27","author":"Li","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110708_bib0500","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diabres.2019.02.006","article-title":"Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study","volume":"149","author":"Patti","year":"2019","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0505","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jdiacomp.2018.11.012","article-title":"Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study","volume":"33","author":"Philis-Tsimikas","year":"2019","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0510","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.clinthera.2016.11.003","article-title":"Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis","volume":"38","author":"McAdam-Marx","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0515","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0520","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.diabres.2019.01.035","article-title":"Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial","volume":"150","author":"Hassanein","year":"2019","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0525","first-page":"31","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus","volume":"1","author":"Van Gaal","year":"2014","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0530","doi-asserted-by":"crossref","first-page":"103538","DOI":"10.1016\/j.bioorg.2019.103538","article-title":"Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties","volume":"95","author":"Cai","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2020.110708_bib0535","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3B, randomized controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet. Diabetes. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0540","doi-asserted-by":"crossref","DOI":"10.1007\/s13300-020-00857-3","article-title":"Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost\u2013Utility Analysis","author":"Men","year":"2020","journal-title":"Diabetes. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0545","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/ijerph17010207","article-title":"Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes","volume":"17","author":"Mirabelli","year":"2020","journal-title":"Int. J. Env. Res. Publ. Health"},{"key":"10.1016\/j.biopha.2020.110708_bib0550","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ebiom.2019.03.057","article-title":"Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis","volume":"44","author":"Liao","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2020.110708_bib0555","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12902-016-0149-z","article-title":"Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study","volume":"16","author":"Sakura","year":"2016","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.biopha.2020.110708_bib0560","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3889\/oamjms.2017.193","article-title":"Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin","volume":"5","author":"Jameshorani","year":"2017","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0565","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.clinthera.2016.10.006","article-title":"Effects of Glimepiride versus Saxagliptin on \u03b2-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin","volume":"38","author":"Perl","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0570","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-8587(14)70251-7","article-title":"Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study","volume":"3","author":"Inagaki","year":"2015","journal-title":"Lancet. Diabetes. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0575","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diabres.2019.05.025","article-title":"Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes","volume":"153","author":"Ito","year":"2019","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0580","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/jdi.12730","article-title":"Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study","volume":"9","author":"Inagaki","year":"2018","journal-title":"J. Diabetes. Invest."},{"key":"10.1016\/j.biopha.2020.110708_bib0585","doi-asserted-by":"crossref","first-page":"e0157509","DOI":"10.1371\/journal.pone.0157509","article-title":"Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism","volume":"11","author":"Grimshaw","year":"2016","journal-title":"PLOS One."},{"key":"10.1016\/j.biopha.2020.110708_bib0590","doi-asserted-by":"crossref","first-page":"107892","DOI":"10.1016\/j.diabres.2019.107892","article-title":"Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin","volume":"158","author":"Nakagawa","year":"2019","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0595","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejphar.2012.09.024","article-title":"A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations","volume":"696","author":"Fukuda-Tsuru","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0600","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jdiacomp.2015.07.002","article-title":"Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring","volume":"29","author":"Wada","year":"2015","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0605","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/DMSO.S106133","article-title":"Teneligliptin in management of type 2 diabetes mellitus","volume":"9","author":"Swami","year":"2016","journal-title":"Diabetes. Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2020.110708_bib0610","article-title":"Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0615","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.6812","article-title":"Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis","author":"Mitra","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2020.110708_bib0620","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1530\/EC-18-0523","article-title":"Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial","volume":"8","author":"Zhou","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.biopha.2020.110708_bib0625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.diabres.2017.10.018","article-title":"A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes","volume":"138","author":"Home","year":"2018","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0630","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s40264-019-00857-8","article-title":"Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus","volume":"42","author":"Kaku","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2020.110708_bib0635","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/1947-2714.128471","article-title":"Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus","volume":"6","author":"Singh","year":"2014","journal-title":"N. Am. J. Med. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0640","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/ijem.IJEM_55_19","article-title":"Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study","volume":"23","author":"Aneja","year":"2019","journal-title":"Indian J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0645","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diabres.2019.01.029","article-title":"Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus","volume":"149","author":"Koike","year":"2019","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0650","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.vhri.2018.06.002","article-title":"Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India","volume":"18","author":"Gupta","year":"2019","journal-title":"Value. Health. Reg. Issues."},{"key":"10.1016\/j.biopha.2020.110708_bib0655","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jdiacomp.2018.10.016","article-title":"An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records","volume":"33","author":"Wysham","year":"2019","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0660","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.clinthera.2017.08.019","article-title":"HbA 1c Outcomes in Patients Treated With Canagliflozin versus Sitagliptin in US Health Plans","volume":"39","author":"Thayer","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0665","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110708_bib0670","doi-asserted-by":"crossref","first-page":"e16575","DOI":"10.1097\/MD.0000000000016575","article-title":"Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus","volume":"98","author":"Feng","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.biopha.2020.110708_bib0675","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jdiacomp.2017.02.001","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure","volume":"31","author":"Kosiborod","year":"2017","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0680","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.pcd.2017.04.004","article-title":"Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up","volume":"11","author":"Wilding","year":"2017","journal-title":"Prim. Care. Diabetes."},{"key":"10.1016\/j.biopha.2020.110708_bib0685","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1038\/s41598-019-43052-6","article-title":"Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population","volume":"9","author":"Al AdAwi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2020.110708_bib0690","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","article-title":"Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes","volume":"38","author":"Kohler","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0695","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/1479164119842513","article-title":"Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies","volume":"16","author":"Liu","year":"2019","journal-title":"Diabetes. Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0700","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13300-019-0566-x","article-title":"Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis","volume":"10","author":"McNeill","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0705","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40265-020-01285-0","article-title":"Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial","volume":"80","author":"Dharmalingam","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2020.110708_bib0710","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.2147\/DDDT.S221093","article-title":"Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy","volume":"14","author":"Mohan","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0715","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1038\/s41598-019-41854-2","article-title":"Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"9","author":"Alam","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2020.110708_bib0720","doi-asserted-by":"crossref","first-page":"19017","DOI":"10.1038\/s41598-019-55466-3","article-title":"Effect of a Dual PPAR \u03b1\/\u03b3 agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial","volume":"9","author":"Jain","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2020.110708_bib0725","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.2337\/dcS15-3007","article-title":"Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes","volume":"39","author":"Cahn","year":"2016","journal-title":"Diabetes. Care."},{"key":"10.1016\/j.biopha.2020.110708_bib0730","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006992.pub2","article-title":"Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control","author":"Vos","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2020.110708_bib0735","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2337\/dc13-1995","article-title":"Clinical and Genetic Determinants of Progression of Type 2 Diabetes: A Direct Study","volume":"37","author":"Zhou","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.biopha.2020.110708_bib0740","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0745","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.2174\/13816128113196660675","article-title":"The Genetic Architecture of Type 2 Diabetes Pharmacotherapy: The Emerging Genomic Evidence","volume":"20","author":"Kavvoura","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2020.110708_bib0750","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jdiacomp.2015.03.004","article-title":"The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care","volume":"29","author":"Khazrai","year":"2015","journal-title":"J Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0755","series-title":"Patient Safety and Quality Improvement","year":"2020"},{"key":"10.1016\/j.biopha.2020.110708_bib0760","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diabres.2018.02.002","article-title":"Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes","volume":"138","author":"Wang","year":"2018","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0765","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.diabres.2016.03.013","article-title":"Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan","volume":"116","author":"Ou","year":"2016","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0770","first-page":"S36","article-title":"Comparative Outcomes of Basal Insulin and Oral Anti-Diabetic Agent As An Add-On to Dual Therapy in Patients with Type 2 Diabetes Mellitus","volume":"21","author":"Chang","year":"2018","journal-title":"Value Health."},{"key":"10.1016\/j.biopha.2020.110708_bib0775","doi-asserted-by":"crossref","first-page":"A360","DOI":"10.1016\/j.jval.2014.08.782","article-title":"An Observational Cohort Study of Diabetes-Associated Secondary Health Care Utilisation in Patients With Type 2 Diabetes Prescribed Dual Combination Therapy With Oral Anti-Hyperglycaemic Agents in the UK","volume":"17","author":"Das","year":"2014","journal-title":"Value Health."},{"key":"10.1016\/j.biopha.2020.110708_bib0780","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.curtheres.2017.01.005","article-title":"Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review","volume":"84","author":"Vijayakumar","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.biopha.2020.110708_bib0785","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.curtheres.2013.10.002","article-title":"The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus","volume":"75","author":"Wang","year":"2013","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0790","first-page":"317","article-title":"Diabetes and oral therapies","volume":"11","author":"Alhadramy","year":"2016","journal-title":"J. Taibah Univ. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0795","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13300-017-0245-8","article-title":"Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","volume":"8","author":"Kay","year":"2017","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0800","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2014.02.004","article-title":"Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats","volume":"729","author":"Jones","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0805","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.diabres.2016.09.014","article-title":"Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP)","volume":"121","author":"Fujitani","year":"2016","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0810","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The Sustained Effects of a Dual GIP\/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0815","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3923\/ijp.2016.422.428","article-title":"Addition of Voglibose to Glimepiride and Metformin have Better Glucose Control in Diabetics: A Prospective, Parallel-group and Open-label Comparative Study","volume":"12","author":"Murti","year":"2016","journal-title":"Int. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0820","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.26452\/ijrps.v10i3.1462","article-title":"Comparative assessment of the efficacy of voglibose and metformin combined with insulin in patients with type 2 diabetes mellitus","volume":"10","author":"Ramalingam","year":"2019","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib0825","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.dsx.2015.09.021","article-title":"Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight\/obese type 2 diabetes","volume":"10","author":"Talaviya","year":"2016","journal-title":"Diabetes. Metab. Syndr."},{"key":"10.1016\/j.biopha.2020.110708_bib0830","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s13300-012-0016-5","article-title":"Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes","volume":"4","author":"Imamura","year":"2013","journal-title":"Diabetes. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0835","article-title":"Beneficial effect of combination therapy with mitiglinide and voglibose on fasting and postprandial endothelial dysfunction in patients with type2 diabetes: a pilot study","volume":"3","author":"Murakami","year":"2017","journal-title":"Integrative Obes Diabetes."},{"key":"10.1016\/j.biopha.2020.110708_bib0840","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.diabres.2013.04.007","article-title":"Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus","volume":"101","author":"Tatsumi","year":"2013","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0845","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.peptides.2019.04.004","article-title":"BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats","volume":"114","author":"Nascimento","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2020.110708_bib0850","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.diabres.2018.08.015","volume":"144","author":"Horie","year":"2018","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0855","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jdiacomp.2018.11.009","article-title":"Efficacy and safety of insulin glargine\/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes","volume":"33","author":"Handelsman","year":"2019","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0860","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110708_bib0865","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.clinthera.2017.10.002","article-title":"Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)","volume":"39","author":"Yu","year":"2017","journal-title":"Clin Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0870","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s40267-019-00670-4","article-title":"Insulin glargine\/lixisenatide in type 2 diabetes: a profile of its use","volume":"35","author":"Deeks","year":"2019","journal-title":"Drugs. Ther. Perspect."},{"key":"10.1016\/j.biopha.2020.110708_bib0875","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jdiacomp.2017.12.005","article-title":"Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring","volume":"32","author":"Yajima","year":"2018","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_bib0880","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0885","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110708_bib0890","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pcd.2019.05.006","article-title":"Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?","volume":"14","author":"Moreno-Fernandez","year":"2020","journal-title":"Prim. Care. Diabetes."},{"key":"10.1016\/j.biopha.2020.110708_bib0895","doi-asserted-by":"crossref","first-page":"311","DOI":"10.14740\/jocmr3677","article-title":"Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study","volume":"11","author":"Takai","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib0900","doi-asserted-by":"crossref","first-page":"108042","DOI":"10.1016\/j.diabres.2020.108042","article-title":"Effectiveness, safety, and tolerability of vildagliptin or vildagliptin\/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study","volume":"162","author":"El Ebrashy","year":"2020","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0905","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.diabres.2016.11.010","article-title":"Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment","volume":"123","author":"Kanazawa","year":"2017","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0910","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diabres.2016.10.016","article-title":"Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring","volume":"122","author":"Yajima","year":"2016","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0915","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4103\/ijem.IJEM_176_17","article-title":"Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial - START Study","volume":"21","author":"Venkataraman","year":"2017","journal-title":"Indian J. Endocr. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0920","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diabres.2015.04.019","article-title":"Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial","volume":"109","author":"Hong","year":"2015","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0925","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13300-017-0358-0","article-title":"Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study","volume":"9","author":"Miller","year":"2018","journal-title":"Diabetes. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0930","doi-asserted-by":"crossref","first-page":"e0129477","DOI":"10.1371\/journal.pone.0129477","article-title":"Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study","volume":"10","author":"Ku","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.biopha.2020.110708_bib0935","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110708_bib0940","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.12875","article-title":"Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial","volume":"19","author":"Ji","year":"2017","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0945","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.clinthera.2017.10.003","article-title":"Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus","volume":"39","author":"Yale","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2020.110708_bib0950","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14740\/jem604","article-title":"Sitagliptin versus Ipragliflozin for Type 2 Diabetes in Clinical Practice","volume":"9","author":"Matsuba","year":"2019","journal-title":"J. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2020.110708_bib0955","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ando.2015.11.003","article-title":"Empagliflozin \/ Linagliptin: Combination therapy in patients with type 2 diabetes","volume":"77","author":"Tan","year":"2016","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.biopha.2020.110708_bib0960","doi-asserted-by":"crossref","first-page":"e004619","DOI":"10.1136\/bmjopen-2013-004619","article-title":"The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomized controlled trials","volume":"4","author":"Sun","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2020.110708_sbref0965a","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jdiacomp.2016.07.016","article-title":"Empagliflozin in combination with oral agents in young and overweight\/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials","volume":"30","author":"Romera","year":"2016","journal-title":"J. Diabetes. Complicat."},{"key":"10.1016\/j.biopha.2020.110708_sbref0970b","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.endonu.2016.06.003","article-title":"Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus","volume":"63","author":"Romera","year":"2016","journal-title":"Endocrinol. Nutr."},{"key":"10.1016\/j.biopha.2020.110708_bib0975","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2019.01.002","article-title":"SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes","volume":"846","author":"Donnan","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib0980","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.numecd.2016.11.007","article-title":"Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes","volume":"27","author":"Gorgojo-Mart\u00ednez","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.biopha.2020.110708_bib0985","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2019.04.008","article-title":"Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study","volume":"151","author":"Ku","year":"2019","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib0990","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(10)60746-5","article-title":"Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomized controlled study","volume":"376","author":"Zinman","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110708_bib0995","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/wnan.1329","article-title":"Recent advances in nanotechnology for diabetes treatment","volume":"7","author":"DiSanto","year":"2015","journal-title":"Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.biopha.2020.110708_bib1000","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2011.09.064","article-title":"Poly-\u0454-caprolactone based formulations for drug delivery and tissue engineering: A review","volume":"158","author":"Dash","year":"2012","journal-title":"J. Control. Release."},{"key":"10.1016\/j.biopha.2020.110708_bib1005","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3109\/10717544.2014.991001","article-title":"Novel drug delivery system: an immense hope for diabetics","volume":"23","author":"Rai","year":"2016","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1010","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1208\/s12249-012-9826-z","article-title":"Improved Bioavailability of a Water-Insoluble Drug by Inhalation of Drug-Containing Maltosyl-\u03b2-Cyclodextrin Microspheres Using a Four-Fluid Nozzle Spray Drier","volume":"13","author":"Ozeki","year":"2012","journal-title":"AAPS Pharmscitech."},{"key":"10.1016\/j.biopha.2020.110708_bib1015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1208\/s12249-019-1325-z","article-title":"Nanoparticles: Oral Delivery for Protein and Peptide Drugs","volume":"20","author":"Cao","year":"2019","journal-title":"AAPS Pharmscitech."},{"key":"10.1016\/j.biopha.2020.110708_bib1020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3762\/bjnano.9.98","article-title":"Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations","volume":"9","author":"Jeevanandam","year":"2018","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.biopha.2020.110708_bib1025","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1080\/10717544.2018.1501119","article-title":"The challenges of oral drug delivery via nanocarriers","volume":"25","author":"Reinholz","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","article-title":"Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic","volume":"26","author":"Puri","year":"2009","journal-title":"Crit. Rev. Ther. Drug."},{"key":"10.1016\/j.biopha.2020.110708_bib1035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","article-title":"The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2020.110708_bib1040","first-page":"404","article-title":"Pharmacokinetic study of niosome-loaded insulin in diabetic rats","volume":"19","author":"Pardakhty","year":"2011","journal-title":"Daru"},{"key":"10.1016\/j.biopha.2020.110708_bib1045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diabres.2017.11.018","article-title":"Nanotechnology based approaches for anti-diabetic drugs delivery","volume":"136","author":"Kesharwani","year":"2018","journal-title":"Diabetes. Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110708_bib1050","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3109\/10717544.2016.1141260","article-title":"Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment","volume":"23","author":"Patel","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/pharmaceutics8030020","article-title":"Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation","volume":"8","author":"Nasr","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2020.110708_bib1060","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3390\/nano9071028","article-title":"Preparation and Characterization of Self Nano-Emulsifying Drug Delivery System Loaded with Citral and Its Antiproliferative Effect on Colorectal Cells In Vitro","volume":"9","author":"Mohd Izham","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.biopha.2020.110708_bib1065","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2020.110708_bib1070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1208\/s12249-013-9926-4","article-title":"Improving Oral Bioavailability and Pharmacokinetics of Liposomal Metformin by Glycerolphosphate\u2013Chitosan Microcomplexation","volume":"14","author":"Manconi","year":"2013","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.biopha.2020.110708_bib1075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpharm.2009.08.013","article-title":"Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect","volume":"382","author":"Hanato","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2020.110708_bib1080","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1080\/10717544.2016.1180723","article-title":"Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes","volume":"23","author":"Zhang","year":"2016","journal-title":"Drug Delivery."},{"key":"10.1016\/j.biopha.2020.110708_bib1085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/0975-1483.57065","article-title":"Development and characterization of niosomal drug delivery of gliclazide","volume":"1","author":"Rathi","year":"2009","journal-title":"J. Young. Pharm."},{"key":"10.1016\/j.biopha.2020.110708_bib1090","first-page":"2756","article-title":"Preparation and in vivo characterization of niosomal carriers of the antidiabetic drug repaglinide","volume":"8","author":"Namdev","year":"2015","journal-title":"Int. J. Pharm. Sci. Nonotech."},{"key":"10.1016\/j.biopha.2020.110708_bib1095","doi-asserted-by":"crossref","DOI":"10.1186\/2008-2231-21-7","article-title":"Metformin loaded non-ionic surfactant vesicles: optimization of formulation, effect of process variables and characterization","volume":"21","author":"Sankhyan","year":"2013","journal-title":"DARU J Pharm Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/10717544.2013.779332","article-title":"Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system","volume":"20","author":"Hasan","year":"2013","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1166\/jpsp.2015.1042","article-title":"Pioglitazone Loaded Vesicular Carriers for Anti-Diabetic Activity: Development and Optimization as Per Central Composite Design","volume":"2","author":"Haider","year":"2015","journal-title":"J. Pharm. Sci. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib1110","doi-asserted-by":"crossref","DOI":"10.1186\/s40199-015-0128-3","article-title":"Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants\/stabilizers on physicochemical properties of nanoparticles","volume":"23","author":"Ebrahimi","year":"2015","journal-title":"DARU J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejps.2017.05.068","article-title":"Evaluation of anti-diabetic activity of glycyrrhizin-loaded nanoparticles in nicotinamide-streptozotocin-induced diabetic rats","volume":"106","author":"Rani","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jphp.12672","article-title":"Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release","volume":"69","author":"Kumar","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib1125","first-page":"1923","article-title":"Chitosan-poly (lactide-co-glycolide) (CS-PLGA) nanoparticles containing metformin HCl: preparation and in vitro evaluation","volume":"27","author":"Gundogdu","year":"2014","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1130","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/10837450.2011.604783","article-title":"Preparation and characterization of metformin hydrochloride loaded-Eudragit\u00aeRSPO and Eudragit\u00aeRSPO\/PLGA nanoparticles","volume":"18","author":"Cetin","year":"2011","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.biopha.2020.110708_bib1135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jcis.2017.04.036","article-title":"Controlled release of metformin from chitosan\u2013based nanocomposite films containing mesoporous MCM-41 nanoparticles as novel drug delivery systems","volume":"501","author":"Shariatinia","year":"2017","journal-title":"J. Colloid. Interface. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1140","first-page":"74","article-title":"Role of Polymeric Excipients on Controlled Release Profile of Glipizide from PLGA and Eudragit RS 100 Nanoparticles","volume":"1","author":"Naha","year":"2013","journal-title":"J. Nanopharm. Drug. Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1145","first-page":"147","article-title":"Formulation and evaluation of glipizide loaded nanoparticles","volume":"5","author":"Lokhande","year":"2013","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1150","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/2468187309666190620145438","article-title":"Development and Characterization of Glipizide Loaded Sustained Release Nanoparticles","volume":"9","author":"Deshmukh","year":"2019","journal-title":"Curr. Nanomed."},{"key":"10.1016\/j.biopha.2020.110708_bib1155","first-page":"301","article-title":"Preparation, characterization and optimization of glipizide controlled release nanoparticles","volume":"9","author":"Emami","year":"2014","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1160","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1208\/s12249-012-9833-0","article-title":"Eudragit-Based Nanosuspension of Poorly Water-Soluble Drug: Formulation and In Vitro\u2013In Vivo Evaluation","volume":"13","author":"Yadav","year":"2012","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.biopha.2020.110708_bib1165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/IJN.S99731","article-title":"Mechanistic analysis of Zein nanoparticles\/PLGA triblock in situ forming implants for glimepiride","author":"Ahmed","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2020.110708_bib1170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.matchemphys.2011.06.049","article-title":"Stabilized amorphous glibenclamide nanoparticles by high-gravity technique","volume":"130","author":"Yu","year":"2011","journal-title":"Mater. Chem. Phys."},{"key":"10.1016\/j.biopha.2020.110708_bib1175","first-page":"1638","article-title":"Formulation and characterization of pioglitazone hydrochloride nanoparticles","volume":"4","author":"Chowdary","year":"2015","journal-title":"World. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1753-0407.2008.00001.x","article-title":"Repaglinide-loaded long-circulating biodegradable nanoparticles: Rational approach for the management of type 2 diabetes mellitus","volume":"1","author":"Jain","year":"2008","journal-title":"J. Diabetes."},{"key":"10.1016\/j.biopha.2020.110708_bib1185","first-page":"1","article-title":"In-vitro observation of repaglinide engineered polymeric nanoparticles","volume":"7","author":"Lekshmi","year":"2012","journal-title":"Dig. J. Nanomater. Biostruct."},{"key":"10.1016\/j.biopha.2020.110708_bib1190","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ejpb.2014.08.004","article-title":"Sol\u2013gel transition of nanoparticles\/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus","volume":"88","author":"Oh","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2020.110708_bib1195","article-title":"Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice","volume":"8","author":"Shi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2020.110708_bib1200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/pharmaceutics11110599","article-title":"Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability","volume":"11","author":"Ismail","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2020.110708_bib1205","doi-asserted-by":"crossref","first-page":"102132","DOI":"10.1016\/j.nano.2019.102132","article-title":"Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide","volume":"24","author":"Uhl","year":"2020","journal-title":"Nanomed. Nanotechnol."},{"key":"10.1016\/j.biopha.2020.110708_bib1210","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3109\/10717544.2015.1077290","article-title":"Nanoemulsion: for improved oral delivery of repaglinide","volume":"23","author":"Akhtar","year":"2015","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1215","first-page":"1","article-title":"Development and evaluation of nanoemulsion of Repaglinide","volume":"1","author":"Nanjwade","year":"2013","journal-title":"Nanotechnol. Nanomed."},{"key":"10.1016\/j.biopha.2020.110708_bib1220","first-page":"292","article-title":"Formulation and characterization of pioglitazone HCl self emulsifying drug delivery system","volume":"5","author":"Bhikshapathi","year":"2013","journal-title":"Der. Pharm. Lett."},{"key":"10.1016\/j.biopha.2020.110708_bib1225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.fjps.2017.02.003","article-title":"SMEDDS of pioglitazone: Formulation, in-vitro evaluation and stability studies","volume":"3","author":"Pandey","year":"2017","journal-title":"Future. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110708_bib1230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0973-8398.134097","article-title":"Formulation and development of self-microemulsifying drug delivery system of pioglitazone hydrochloride","volume":"8","author":"Madan","year":"2014","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.biopha.2020.110708_bib1235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.colsurfb.2014.11.022","article-title":"Self emulsifying drug delivery system for enhanced solubility and dissolution of glipizide","volume":"126","author":"Agrawal","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2020.110708_bib1240","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/10717544.2013.879753","article-title":"Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride: development and antidiabetic activity in albino rabbits","volume":"22","author":"Mohd","year":"2014","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpb.2016.02.012","article-title":"Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide","volume":"102","author":"Gon\u00e7alves","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2020.110708_bib1250","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/03639040903585143","article-title":"Glibenclamide-loaded self-nanoemulsifying drug delivery system: development and characterization","volume":"36","author":"Singh","year":"2010","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.biopha.2020.110708_bib1255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/156720110790396472","article-title":"Development of Repaglinide Loaded Solid Lipid Nanocarrier: Selection of Fabrication Method","volume":"7","author":"Rawat","year":"2010","journal-title":"Curr. Drug. Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1260","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jphp.12537","article-title":"Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug","volume":"68","author":"Ebrahimi","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110708_bib1265","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s13318-014-0213-x","article-title":"A comparative study on effect of metformin and metformin-conjugated nanotubes on blood glucose homeostasis in diabetic rats","volume":"40","author":"Mirazi","year":"2014","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"10.1016\/j.biopha.2020.110708_bib1270","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53996-4","article-title":"Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model","volume":"9","author":"Panda","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2020.110708_bib1275","first-page":"108","article-title":"Preparation and characterization of metformin proniosomal gel for treatment of diabetes mellitus","volume":"15","author":"Gupta","year":"2012","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"10.1016\/j.biopha.2020.110708_bib1280","first-page":"137","article-title":"Solid lipid nanoparticles as a carrier of metformin for transdermal delivery","volume":"5","author":"Sharma","year":"2013","journal-title":"Int. J. Drug. Deliv."},{"key":"10.1016\/j.biopha.2020.110708_bib1285","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/17425247.2014.906402","article-title":"Optimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patches","volume":"11","author":"Ahmed","year":"2014","journal-title":"Expert. Opin. Drug. Del."},{"key":"10.1016\/j.biopha.2020.110708_bib1290","first-page":"1077","article-title":"Transdermal delivery of repaglinide from solid lipid nanoparticles in diabetic rats: in vitro and in vivo studies","volume":"3","author":"Vijayan","year":"2011","journal-title":"J. Pharm. Sci. Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030901X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030901X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:49:24Z","timestamp":1766083764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222030901X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":258,"alternative-id":["S075333222030901X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110708","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type II diabetes mellitus: a review on recent drug based therapeutics","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110708"}}